New Delhi

Cipla Ltd on Wednesday reported a sharp decline in its consolidated net profit for the fourth quarter of FY26, with earnings falling 55.32 per cent year-on-year to Rs 542.51 crore, impacted by lower revenue from its North American operations and higher expenditure.

The drugmaker had posted a consolidated net profit of Rs 1,214.14 crore in the corresponding quarter of the previous financial year, according to a regulatory filing.

Revenue from operations during the January-March quarter stood at Rs 6,541.2 crore, marginally lower than Rs 6,729.69 crore recorded in the same period last year.

Sales in the North American market declined 26 per cent to Rs 1,414 crore during the quarter, compared with Rs 1,919 crore a year earlier. In contrast, the company’s “One India” business delivered strong growth, with revenue rising 15 per cent to Rs 3,007 crore from Rs 2,622 crore in the year-ago period.

Total expenses for the quarter increased to Rs 5,982.3 crore from Rs 5,514.85 crore in the corresponding period of the previous fiscal.

The company’s board, at its meeting held on Wednesday, recommended a final dividend of Rs 13 per equity share of face value Rs 2 each for FY26, subject to approval by shareholders at the upcoming annual general meeting.

For the full financial year ended March 31, 2026, Cipla posted a consolidated net profit of Rs 3,861.74 crore, down from Rs 5,269.2 crore in FY25.

Despite the drop in profit, annual revenue from operations rose to Rs 28,162.59 crore, compared with Rs 27,547.62 crore in the previous fiscal.

Managing Director and Global CEO Achin Gupta said the company achieved its highest-ever annual revenue in FY26, reflecting resilience across its core businesses despite temporary challenges in some markets.

He noted that the One India business crossed the Rs 12,500-crore annual revenue mark, supported by double-digit growth in key prescription therapies, continued momentum in trade generics, and steady leadership of major consumer health brands.

Gupta added that the US business generated annual revenue of USD 780 million, driven by demand for differentiated products and a stable base portfolio, while emerging markets and Europe together crossed the USD 400 million annualised revenue milestone.

READ MORE: Abeda Inamdar left a cushy job to change lives through education, social reform

Looking ahead, he said the company will continue to focus on expanding its presence in key markets, strengthening flagship brands, investing in future product pipelines, and addressing regulatory priorities.